One-year results demonstrate improved disease control and quality of life in hereditary angioedema patients switching to donidalorsen, suggesting its viability as a treatment option.
In patients who switched from another LTP, donidalorsen was well tolerated and improved long-term HAE attack rates, quality of life, and disease control.
No takes yet. Share an insight, caveat, or question.
Riedl et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: